老年抗脂综合征的特征和预后:一个观察性队列研究
Liang Luo1,2, Qingmeng Cai2, Xiangjun Liu2
1Department of Chinese Medicine, The People's Hospital of Yubei District of Chongqing City, Chongqing, China.
Lupus
|July 21, 2024
概括
老年开始的抗脂综合征 (APS) 呈现不同,随着中风风险增加和死亡率增加. 早期治疗并发症对于年龄较大的APS患者获得更好的结果至关重要.
科学领域:
- 类风湿病学 类风湿病学
- 内部医学 内部医学
- 老年病的医生 老年病的医生
背景情况:
- 抗脂综合征 (APS) 是一种自身免疫性疾病,主要影响年轻人.
- 在老年患者中诊断APS是具有挑战性的,因为其症状与其他血栓友爱障碍重叠.
- 了解老年发病APS的独特特征对于有效管理至关重要.
研究的目的:
- 调查老年发病的APS (≥60岁) 的独特临床特征.
- 为了比较老年发病的APS与非老年发病的APS和老年非APS患者的预后.
- 为了确定影响老年患者APS的结果的因素.
主要方法:
- 观察性队列研究,包括从2009年至2022年的血栓性APS患者.
- 对比老年发病的APS患者 (≥60岁) 与非老年发病的APS患者 (<60岁) 和老年非APS对照 (≥60岁与血栓形成).
- 临床特征,心血管风险因素,抗脂抗体阳性和死亡率的分析.
主要成果:
- 老年发病的APS患者 (45/161) 发病时中风的发病率较高 (35.6%vs18.1%) 和更多的心血管风险因素.
- 在老年发病的APS患者中观察到较低的阳性率和狼抗凝剂比率 (51.1%对71.6%).
- 在老年发病的APS患者中发现了显著更高的10年累积全因死亡率 (p < .001) 和APS相关死亡率.
结论:
- 老年发病的APS表现出独特的特征,包括更高的中风患病率和独特的抗体配置文件.
- 这些患者面临着显著增加的10年死亡率,无论是整体还是与APS相关的.
- 及时识别并发症和管理对于减轻老年APS患者的血栓复发和死亡率至关重要.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
414
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
323
相关概念视频
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:38Inflammation
53.3K
Overview
53.3K
01:15Parkinson's Disease: Overview
517
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
517
01:20COPD: Pathogenesis and Clinical Features
252
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
252
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
668
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
668
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
165
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
165